Brief: Curasight Says Co Submits Clinical Trial Application For Phase 2 Trial With Utrace In Prostate Cancer Patients
18/12/2023 17:33
Dec 18 (Reuters) - Curasight A/S CURAS.TE :
* SUBMITS CLINICAL TRIAL APPLICATION (CTA) FOR PHASE 2 TRIAL
WITH
UTRACE ® IN PROSTATE CANCER PATIENTS
* COMPANY ON TRACK TO DOSE FIRST PATIENT IN 2Q 2024
Source text for Eikon: ID:nWkr2R3t8
Further company coverage: CURAS.TE
((Reuters.Briefs@thomsonreuters.com;))